nifedipine has been researched along with Renal Insufficiency, Chronic in 11 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a prospective, multicenter, observational study, Chinese patients with CKD and uncontrolled hypertension were given nifedipine GITS 60 mg with a primary endpoint of change in office systolic BP (SBP) at 12 weeks." | 8.02 | Effectiveness and Tolerability of Nifedipine GITS in Patients with Chronic Kidney Disease and Uncontrolled Hypertension: A Prospective, Multicenter, Observational Study (ADRENAL). ( Chen, J; Chen, Q; Cheng, H; Hong, F; Huang, J; Li, R; Li, W; Liu, C; Liu, J; Lv, R; Shen, S; Song, W; Wang, H; Wang, J; Wei, L; Wu, H; Xiao, H; Yu, F; Zhang, T; Zhang, X, 2021) |
| " Next, in a randomized double-blind crossover study of 27 subjects with proteinuric CKD, we examined the effects of 6 weeks of treatment with placebo, sitaxentan (endothelin A antagonist), and nifedipine on these peptides alongside the primary end points of proteinuria, blood pressure, and arterial stiffness." | 5.20 | Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism. ( Chariyavilaskul, P; Corder, R; Dhaun, N; Goddard, J; Kimmitt, RA; MacIntyre, IM; Webb, DJ; Wood, EG; Yuzugulen, J, 2015) |
| " We conducted a randomized, double-blind, three-way crossover study in 27 patients with proteinuric CKD to compare the effects of the ET(A) receptor antagonist sitaxentan, nifedipine, and placebo on proteinuria, BP, arterial stiffness, and various cardiovascular biomarkers." | 5.17 | Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. ( Blackwell, S; Dhaun, N; Goddard, J; Johnston, NR; Melville, V; Talwar, DK; Webb, DJ, 2013) |
| "In a prospective, multicenter, observational study, Chinese patients with CKD and uncontrolled hypertension were given nifedipine GITS 60 mg with a primary endpoint of change in office systolic BP (SBP) at 12 weeks." | 4.02 | Effectiveness and Tolerability of Nifedipine GITS in Patients with Chronic Kidney Disease and Uncontrolled Hypertension: A Prospective, Multicenter, Observational Study (ADRENAL). ( Chen, J; Chen, Q; Cheng, H; Hong, F; Huang, J; Li, R; Li, W; Liu, C; Liu, J; Lv, R; Shen, S; Song, W; Wang, H; Wang, J; Wei, L; Wu, H; Xiao, H; Yu, F; Zhang, T; Zhang, X, 2021) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| "This study employed population pharmacokinetic (PopPK) modeling to delineate potential changes in CYP3A activity in patients with CKD." | 1.72 | Population Pharmacokinetic Modelling for Nifedipine to Evaluate the Effect of Parathyroid Hormone on CYP3A in Patients with Chronic Kidney Disease. ( Fu, C; Guo, C; Li, W; Liang, W; Liu, J; Pei, Q; Tan, H; Yang, B; Yang, G; Zhang, H, 2022) |
| " The new model is useful for estimating the risk of drug interaction in clinical practice when AST-120 is used in combination with other drugs." | 1.43 | Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs. ( Kotegawa, T; Koya, Y; Machi, Y; Namiki, N; Shobu, Y; Uchida, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, C | 1 |
| Pei, Q | 1 |
| Liang, W | 1 |
| Yang, B | 1 |
| Li, W | 2 |
| Liu, J | 2 |
| Tan, H | 1 |
| Guo, C | 1 |
| Zhang, H | 1 |
| Yang, G | 1 |
| Wei, Y | 1 |
| Wang, Y | 1 |
| Yao, Q | 1 |
| Zhou, L | 1 |
| Fu, P | 1 |
| Peng, CC | 2 |
| Chen, CR | 2 |
| Chen, CY | 2 |
| Lin, YC | 2 |
| Chen, KC | 2 |
| Peng, RY | 1 |
| Wang, JC | 1 |
| Wu, MS | 1 |
| Lin, YF | 1 |
| Lv, R | 1 |
| Chen, J | 1 |
| Wang, H | 1 |
| Wang, J | 1 |
| Cheng, H | 1 |
| Li, R | 1 |
| Zhang, T | 1 |
| Wei, L | 1 |
| Chen, Q | 1 |
| Huang, J | 1 |
| Yu, F | 1 |
| Shen, S | 1 |
| Wu, H | 1 |
| Liu, C | 1 |
| Hong, F | 1 |
| Zhang, X | 1 |
| Xiao, H | 1 |
| Song, W | 1 |
| Reddy, S | 1 |
| Jim, B | 1 |
| Imanishi, M | 1 |
| Ishizawa, K | 1 |
| Sakurada, T | 1 |
| Ishizawa, Y | 1 |
| Yamano, N | 1 |
| Kihira, Y | 1 |
| Ikeda, Y | 1 |
| Tsuchiya, K | 1 |
| Tamaki, T | 1 |
| Dhaun, N | 2 |
| Yuzugulen, J | 1 |
| Kimmitt, RA | 1 |
| Wood, EG | 1 |
| Chariyavilaskul, P | 1 |
| MacIntyre, IM | 1 |
| Goddard, J | 2 |
| Webb, DJ | 2 |
| Corder, R | 1 |
| Koya, Y | 1 |
| Uchida, S | 1 |
| Machi, Y | 1 |
| Shobu, Y | 1 |
| Namiki, N | 1 |
| Kotegawa, T | 1 |
| Kobayashi, N | 1 |
| Ishimitsu, T | 1 |
| Melville, V | 1 |
| Blackwell, S | 1 |
| Talwar, DK | 1 |
| Johnston, NR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study[NCT03194633] | 871 participants (Actual) | Observational | 2017-07-10 | Completed | |||
| THE EFFECTS OF SITAXSENTAN ONCE DAILY DOSING ON PROTEINURIA, 24-HOUR BLOOD PRESSURE, AND ARTERIAL STIFFNESS IN SUBJECTS WITH CHRONIC KIDNEY DISEASE[NCT00810732] | Phase 2 | 27 participants (Actual) | Interventional | 2007-05-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Carotid-femoral pulse wave velocity (PWV), a measure of arterial stiffness, is determined from the time taken for the arterial pulse to propagate from the carotid to the femoral artery. Baseline was defined as the pre-dose measurement for the measure collected at Week 0 of each treatment period. Week 3 and Week 6 was an average of measurement for the measure collected at Week 3 and 6 of each treatment period. (NCT00810732)
Timeframe: Baseline, Week 3 and 6
| Intervention | Meter per second (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 3 | Change at Week 6 | |
| Nifedipine | 7.94 | -0.21 | -0.38 |
| Placebo | 7.74 | -0.21 | 0.29 |
| Sitaxsentan | 7.97 | -0.19 | -0.41 |
Mean urine total protein assessment included 24-hour urine collections to assess total protein excretion per 24 hours. Baseline was derived from an average of Week 0 (pre-dose) 24-hour urine collections prior to each treatment period. Week 6 was derived from an average of Week 6 24-hour urine collections for each treatment period. (NCT00810732)
Timeframe: Baseline, Week 6
| Intervention | Grams per 24 hours (Mean) | |
|---|---|---|
| Baseline | Change at week 6 | |
| Nifedipine | 1.95 | 0.01 |
| Placebo | 2.07 | -0.06 |
| Sitaxsentan | 2.07 | -0.62 |
The 24-hour ambulatory BP monitoring was performed by using a BP cuff which was attached to the participant's arm, using the same arm throughout the study, with a small monitor that comfortably sits in the pocket of participant. Mean values over 24-hour measurements at each measurement period were calculated. The change in total 24-hour ambulatory monitoring of systemic arterial BP, SBP and DBP at Week 3 and 6 relative to baseline were reported. Baseline was as an average of the pre-dose measurement for the measure collected at Week 0 of each treatment period. Week 3 and Week 6 was an average of measurement for the measure collected at Week 3 and 6 of each treatment period. (NCT00810732)
Timeframe: Baseline, Week 3 and 6
| Intervention | Millimeter of Mercury (mmHg) (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean Systemic Arterial BP: Baseline | Mean Systemic Arterial BP: Change at Week 3 | Mean Systemic Arterial BP: Change at Week 6 | Mean Systemic Arterial SBP :Baseline | Mean Systemic Arterial SBP: Change at Week 3 | Mean Systemic Arterial SBP: Change at Week 6 | Mean Systemic Arterial DBP: Baseline | Mean Systemic Arterial DBP: Change at Week 3 | Mean Systemic Arterial DBP: Change at Week 6 | |
| Nifedipine | 93.78 | -2.95 | -3.54 | 125.12 | -4.20 | -4.47 | 78.27 | -2.09 | -2.86 |
| Placebo | 92.98 | -1.20 | -0.35 | 125.17 | -2.81 | -1.57 | 77.58 | -0.86 | -0.41 |
| Sitaxsentan | 92.94 | -4.59 | -3.74 | 124.03 | -4.88 | -3.99 | 77.56 | -4.85 | -3.60 |
2 reviews available for nifedipine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
[Drug development for cardiorenal disease based on oxidative stress control].
Topics: Animals; Cardiovascular Diseases; Humans; Nifedipine; Nitric Oxide; Nitroso Compounds; Oxidative Str | 2014 |
2 trials available for nifedipine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism.
Topics: Adult; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method | 2015 |
Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.
Topics: Adult; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; | 2013 |
7 other studies available for nifedipine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Population Pharmacokinetic Modelling for Nifedipine to Evaluate the Effect of Parathyroid Hormone on CYP3A in Patients with Chronic Kidney Disease.
Topics: Cytochrome P-450 CYP3A; Humans; Models, Biological; Nifedipine; Parathyroid Hormone; Renal Insuffici | 2022 |
Successful management of twin pregnancy in a woman with advanced chronic kidney disease: A case report.
Topics: Adult; Cesarean Section; China; Creatinine; Female; Glucocorticoids; Humans; Infant, Newborn; Nifedi | 2019 |
Nifedipine Upregulates ATF6-α, Caspases -12, -3, and -7 Implicating Lipotoxicity-Associated Renal ER Stress.
Topics: Activating Transcription Factor 6; Animals; Biomarkers; Caspase 12; Caspase 3; Caspase 7; Caspases; | 2020 |
Nifedipine Exacerbates Lipogenesis in the Kidney via KIM-1, CD36, and SREBP Upregulation: Implications from an Animal Model for Human Study.
Topics: Animals; CD36 Antigens; Diet, High-Fat; Disease Models, Animal; Doxorubicin; Female; Gene Expression | 2020 |
Effectiveness and Tolerability of Nifedipine GITS in Patients with Chronic Kidney Disease and Uncontrolled Hypertension: A Prospective, Multicenter, Observational Study (ADRENAL).
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Nifedipine; Prospective Studies; Rena | 2021 |
Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs.
Topics: Administration, Oral; Adsorption; Aluminum Hydroxide; Amlodipine; Aspirin; Carbon; Drug Interactions | 2016 |
Assessment on antihypertensive effect and safety of nifedipine controlled-release tablet administered at 80 mg/day in practical clinic.
Topics: Adult; Age Factors; Aged; Ambulatory Care Facilities; Amlodipine; Antihypertensive Agents; Blood Pre | 2012 |